Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 16/20 | 1.00 |
| ▸ | LCLAT1 | Q6UWP7 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16384061 | 1.00 | SMO (1.00) | SMOLCLAT1MAPTUSP2TSHR | |
| SCHEMBL26673986 | 0.90 | SMO (0.81) | SMOLCLAT1MAPTSMN1; SMN2 | |
| SCHEMBL24473959 | 0.84 | SMO (0.72) | SMOLCLAT1MAPTUSP2TSHR | |
| SCHEMBL26078521 | 0.84 | SMO (0.72) | SMOMAPTUSP2TSHRMAPK1 | |
| SCHEMBL30587154 | 0.84 | SMO (0.72) | SMOLCLAT1MAPTUSP2TSHR | |
| SCHEMBL4260914 | 0.84 | SMO (1.00) | SMOMAPTTSHRMAPK1HSD17B10 | |
| SCHEMBL4255817 | 0.82 | SMO (1.00) | SMOMAPT | |
| SCHEMBL4255790 | 0.82 | SMO (0.72) | SMOMAPT | |
| SCHEMBL4266575 | 0.82 | SMO (1.00) | SMOMAPT | |
| SCHEMBL4262829 | 0.82 | SMO (1.00) | SMOMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116457353-A | N-substituted 4- (5-phenyl-1, 3, 4-oxadiazol-2-yl) anilines for the treatment and prophylaxis of hepatitis b virus infections | 豪夫迈·罗氏有限公司 | 2023-07-18 | — | — | CN | claimed |
| CN-116457353-A | N-substituted 4- (5-phenyl-1, 3, 4-oxadiazol-2-yl) anilines for the treatment and prophylaxis of hepatitis b virus infections | 豪夫迈·罗氏有限公司 | 2023-07-18 | — | — | CN | disclosed |